Polaris House, North Star Avenue, Swindon, SN2 1FL, UK.
Regen Med. 2021 Mar;16(3):295-308. doi: 10.2217/rme-2020-0149. Epub 2021 Mar 25.
The relationship between regenerative medicine innovators and the clinics that will use their inventions continues to evolve. In the UK, the Advanced Therapy Treatment Centres exemplify this. The agents in the value chain are becoming collaborators in a shared innovation process. This paper proposes a larger role for systems engineering in this change and a cost-based representation of institutional readiness in designing suitable operational models for clinical adoption. The proposed approach places this value in a whole-lifetime cost framework. The current value for the adoption process can then be estimated for comparison with the sum of the adoption costs, the costs of operating at steady state and, if need be, replacement costs at end of life of the innovation.
再生医学创新者与将使用他们发明的临床机构之间的关系不断发展。在英国，先进治疗中心就是一个典型范例。价值链中的各个环节正在成为共同创新过程中的合作伙伴。本文提出在这种变革中系统工程应发挥更大作用，并提出以成本为基础的机构准备情况表示法，为临床采用设计合适的运营模式。所提议的方法将这种价值置于整个生命周期成本框架中。然后，可以对采用过程的当前价值进行估算，以便与采用成本、稳定状态下的运营成本以及在创新生命周期结束时的更换成本之和进行比较。
